Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Buparlisib · AN2025, BKM-120

Small molecule · Inhibitor of phosphatidylinositol 3-kinase (PI3K) class I · developed by Novartis Pharmaceuticals

Phase 3 Most advanced trial (none active)

2 Registered trials

What is Buparlisib?

Buparlisib is an orally bioavailable pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor that acts in an ATP-competitive manner, reducing production of phosphatidylinositol-3,4,5-trisphosphate and dampening PI3K/AKT signaling. It is being studied in head and neck cancer and locally advanced solid tumors, in combination with paclitaxel.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AN2025, BKM-120, BKM120-AAA
Drug type: Small molecule
Targets: phosphatidylinositol 3-kinase (PI3K) class I
Mechanism: Inhibitor of phosphatidylinositol 3-kinase (PI3K) class I
Pathways: PI3K/AKT signaling pathway
Therapy area: Oncology
Developer: Novartis Pharmaceuticals
In trials of: ANL
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 0ZM2Z182GD

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04338399	Phase 3	Head and Neck Cancer	Completed	ANL
NCT04975958	Phase 1	Locally Advanced Solid Tumor	Completed	ANL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck CancerLocally Advanced Solid Tumor

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z